TG Therapeutics, Inc. (TGTX)

TG Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	482.58	79.15	179.89	92.93	102.3	298.89
Short-Term Investments	69.67	62.82	131.11	124.58	59.37	15.88
Cash & Short-Term Investments	552.25	141.97	311	217.51	161.68	314.76
Cash Growth	119.26%	-54.35%	42.98%	34.53%	-48.63%	-48.01%
Accounts Receivable	401.57	305.63	129.19	51.09	-	1.39
Receivables	401.57	305.63	129.19	51.09	-	1.39
Inventory	147.97	125.59	110.46	39.82	-	-
Other Current Assets	43.9	57.58	15.72	9.52	6.6	14.81
Total Current Assets	1,146	630.76	566.36	317.94	168.27	330.97
Property, Plant & Equipment	7.09	6.28	7.15	8.05	9.2	9.23
Long-Term Investments	64.37	59.14	0.81	-	12.4	35.53
Goodwill	-	-	-	-	0.8	0.8
Long-Term Deferred Tax Assets	343.43	348	-	-	-	-
Long-Term Deferred Charges	-	-	-	-	1.63	1.84
Other Long-Term Assets	79.06	19.08	3.37	3.59	1.27	1.26
Total Assets	1,640	1,063	577.69	329.59	193.57	379.63

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	120.09	47.41	37.4	29.27	42.02	50.89
Accrued Expenses	59.51	41.05	15.19	12.17	8.43	10.17
Current Portion of Long-Term Debt	-	0.69	0.66	0.36	0.24	1.34
Current Portion of Leases	1.91	1.04	1.16	1.45	1.58	1.44
Current Unearned Revenue	16.83	21.23	11.41	0.15	-	0.2
Other Current Liabilities	70.16	42.34	24.87	10.32	0.93	1.35
Total Current Liabilities	268.49	153.76	90.68	53.72	53.2	65.38
Long-Term Debt	745.39	245.65	244.43	100.12	71.14	66.79
Long-Term Leases	7.14	7.02	8.13	9.23	10.34	9.85
Long-Term Unearned Revenue	14.53	8.81	12.09	6.02	0.31	0.46
Total Liabilities	1,036	415.23	355.33	169.09	134.99	142.48

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.16	0.16	0.16	0.15	0.15	0.14
Additional Paid-In Capital	1,859	1,830	1,760	1,713	1,586	1,566
Retained Earnings	-1,054	-1,082	-1,529	-1,553	-1,527	-1,329
Treasury Stock	-200.23	-100.23	-8.99	-0.23	-0.23	-0.23
Shareholders' Equity	604.08	648.02	222.36	160.5	58.59	237.15
Total Liabilities & Equity	1,640	1,063	577.69	329.59	193.57	379.63

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	754.44	254.4	254.38	111.15	83.3	79.41
Net Cash (Debt)	-202.19	-112.43	56.62	106.36	78.38	235.36
Net Cash Growth	-	-	-46.76%	35.70%	-66.70%	-58.16%
Net Cash Per Share	-1.27	-0.70	0.35	0.72	0.58	1.78
Filing Date Shares Outstanding	141.85	147.68	145.23	144.78	137.63	130.79
Total Common Shares Outstanding	141.86	143.29	143.99	141.79	137.65	131.22
Working Capital	877.19	477	475.68	264.22	115.07	265.58
Book Value Per Share	4.26	4.52	1.54	1.13	0.43	1.81
Tangible Book Value	604.08	648.02	222.36	160.5	57.79	236.35
Tangible Book Value Per Share	4.26	4.52	1.54	1.13	0.42	1.80

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Aug 3, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 20, 2026

Data Sources Report a data error